To assess the utility of the pY1586 ALK immunoassay to measure pharmacodynamic changes in an animal model treated with crizotinib or ceritinib, ALK phosphorylation status was quantified in ex vivo tumor tissue (Fig. 4, Section Author contributions). Here, ALK is linked to neoplasm.